Share of commercial users, such as oil companies or consumers, was far larger in London than in New York, the data published last week show.

Licensing typically involves upfront fees, plus a promised share of royalties should the molecule become a commercial drug.

As additional products enter the marketplace, commercial sales will make up an increasingly large share of total fuel cell expenditures.